Chen M, Hricak H, Kalbhen C L, Kurhanewicz J, Vigneron D B, Weiss J M, Carroll P R
Department of Radiology, University of California San Francisco 94143-0628, USA.
AJR Am J Roentgenol. 1996 May;166(5):1157-63. doi: 10.2214/ajr.166.5.8615261.
The purpose of our study was to evaluate the effect of androgen deprivation therapy on the MR imaging findings of prostate gland anatomy and cancer pathology in men with prostatic cancer treated with hormonal ablation before radical prostatectomy.
Twenty-two patients (mean age, 66 years old) were divided into two groups: in group I (n=10), MR imaging studies were done before and after hormonal treatment; in group II (n=12), MR imaging studies were done only after hormonal treatment. MR imaging was performed on a 1.5 T-scanner (Signa; General Electric Medical Systems, Milwaukee, WI) and included transverse plane phased-array coil T1-weighted images (TR/TE, 600/12), combined endorectal phased-array coil transverse plane T1-weighted images, fast spin-echo T2-weighted (4000/102), and coronal plane fast spin-echo T2-weighted images. Image evaluation was by consensus and included assessment of the gland size, signal intensity, tumor depiction, extracapsular extension, seminal vesicle invasion, and overall staging accuracy (Jewett and Whitmore classification). MR imaging findings were correlated with pathologic findings of step section radical prostatectomy.
After hormonal therapy, the volume of the prostate gland showed a mean decrease of 33.5% +/- 19.6% SD (range, 0-64%). Volume reduction in the transition zone (mean 29.2% +/- 22% SD) was less than in the peripheral zone (mean, 55.8% +/- 25.8% SD) (p < .05). On T2-weighted images, the peripheral zone showed homogeneous decreases in signal intensity in 13 of 22 (58%) patients. Compared with pathologic findings, the accuracy of tumor detection by MR imaging was 74% (98 of 132 sites). Tumor presence was overestimated in 32 of 132 (24%) sites. Overall staging accuracy after hormonal ablation was 68% (15 of 22). The positive predictive value and negative predictive value for extracapsular extension were 57% (13 of 23 sites) and 90% (19 of 21 sites), respectively, and for seminal vesicle invasion were 80% (8 of 10 sites) and 97% (33 of 34 sites), respectively.
As detected by MR imaging, hormonal ablation caused a decrease in size and signal intensity of the prostate gland and seminal vesicles and overestimation of tumor presence and extracapsular extension.
本研究旨在评估雄激素剥夺疗法对前列腺癌患者在根治性前列腺切除术前行激素消融治疗后前列腺解剖结构的磁共振成像(MR)表现及癌病理的影响。
22例患者(平均年龄66岁)分为两组:I组(n = 10),在激素治疗前后均进行MR成像研究;II组(n = 12),仅在激素治疗后进行MR成像研究。MR成像在1.5T扫描仪(Signa;通用电气医疗系统公司,威斯康星州密尔沃基)上进行,包括横断面上的相控阵线圈T1加权图像(TR/TE,600/12)、直肠内相控阵线圈联合横断面上的T1加权图像、快速自旋回波T2加权图像(4000/102)以及冠状面上的快速自旋回波T2加权图像。图像评估采用共识法,包括对腺体大小、信号强度、肿瘤显示、包膜外侵犯、精囊侵犯以及总体分期准确性(Jewett和Whitmore分类)的评估。MR成像结果与根治性前列腺切除标本的病理结果相关。
激素治疗后,前列腺体积平均减少33.5%±19.6%标准差(范围0 - 64%)。移行带体积减少(平均29.2%±22%标准差)小于外周带(平均55.8%±25.8%标准差)(p < 0.05)。在T2加权图像上,22例患者中有13例(58%)外周带信号强度均匀降低。与病理结果相比,MR成像检测肿瘤的准确性为74%(132个部位中的98个)。132个部位中有32个(24%)肿瘤存在被高估。激素消融后的总体分期准确性为68%(22例中的15例)。包膜外侵犯的阳性预测值和阴性预测值分别为57%(23个部位中的13个)和90%(21个部位中的19个),精囊侵犯的阳性预测值和阴性预测值分别为80%(10个部位中的8个)和97%(34个部位中的33个)。
通过MR成像检测发现,激素消融导致前列腺和精囊大小及信号强度降低,肿瘤存在及包膜外侵犯被高估。